A Study Evaluating APG777 in Atopic Dermatitis
← catalyst calendarNCT06395948 · readout ≤ 103 d
Sponsored by Apogee Therapeutics, Inc. (industry) · APGE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
470actual
Sites
94
Countries
Canada, Czechia, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-29 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: APG777
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Percent Change From Baseline in Eczema Area and Severity Index (EASI)
measured Baseline and at Week 16
Part B: Proportion of participants who achieve EASI 75 at Week 16
measured At Week 16
Publications
- PMID 41422501 — linked by the registry
- PMID 40739793 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · APGE's whole pipeline · Catalyst calendar · Every registered study · What changed